Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic

Tereza Popkova, Ludek Pour, Ivan Spicka, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Tomas Jelinek, Petr Pavlicek, Marta Krejci, Jan Straub, Vladimir Maisnar, Tereza Dekojova, Tomas Pika, Jan Soukup, Lenka Capkova, Roman Hájek

Blood (2021) 138 (Supplement 1): 4894.

https://doi.org/10.1182/blood-2021-153978

Published: 2021

Journal Articles

Tumor Specific cfDNA Predicts Treatment Response of Multiple Myeloma Patients

David Vrabel, MSc, Jana Gregorova, MSc., Lenka Sedlarikova, MSc, Martina Almasi, Ing.,PhD, Renata Bezděková, MSc., Martin Stork, MD, Marta Krejci, Prof, MD PhD, Zdenek Adam, Prof, MD CSc, Ludek Pour, MD, Roman Hajek, MD PhD, Sabina Sevcikova, PhD

Blood (2018) 132 (Supplement 1): 3188.

https://doi.org/10.1182/blood-2018-99-114793

Published: 2018

Journal Articles

Diagnostic Relevance of 18F-FDG PET/CT in Newly Diagnosed Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) : Single- Center Experience

Viera Sandecka, MD PhD, Ludek Pour, MD, Zdenek Adam, Prof, MD CSc, Martin Stork, MD, Marta Krejci, Prof, MD PhD, Jana Michalcova, MD, Zdenek Kral, MD CSc, Sabina Sevcikova, PhD, Zdeněk Řehák, MD PhD, Renata Koukalova, MD

Blood (2018) 132 (Supplement 1): 1913.

https://doi.org/10.1182/blood-2018-99-111094

Published: 2018

Journal Articles

Risk Factors Associated with Development of Extramedullary Disease in Multiple Myeloma

Blood (2018) 132 (Supplement 1): 5596.

https://doi.org/10.1182/blood-2018-99-114854

Published: 2018

Journal Articles

Bortezomib-Based Induction Treatment for Patients with Multiple Myeloma Ineligible for Autologous Stem Cell Transplantation: A Retrospective Multicenter Study in Czech Republic

Viera Sandecka, MD, Ludek Pour, Doc,MD PhD, Sabina Sevcikova, RNDr, PhD, Lucie Brozova, MSc, Jan Straub, MD, Vlastimil Scudla, Prof, MD CSc, Vladimir Maisnar, Prof, MD PhD, Petr Pavlicek, MD, Zdenek Adam, Prof, MD CSc, Marta Krejci, Prof, MD PhD, Martin Stork, MD, Tomas Jelinek, Hana Plonkova, Roman Hajek

Blood (2017) 130 (Supplement 1): 5435.

https://doi.org/10.1182/blood.V130.Suppl_1.5435.5435

Published: 2017

Journal Articles

Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry

Marlijn Hoeks, MD, Saskia Langemeijer, MD PhD, Louise De Swart, MD, Tim Bagguley, Corine van Marrewijk, PhD, David Bowen, MD PhD, Jaroslav Cermak, Eva Hellstrom-Lindberg, MD PhD, Aurelia Tatic, MD, Argiris Symeonidis, Marian G.J. Van Kraaij, MD PhD, Panagiotis Panagiotidis, Hege Garelius, MD, Dominic J Culligan, Marta Krejci, MD PhD, Jackie Droste, PhD, Alexandra Smith, PhD, Dorine W. Swinkels, MD PhD, Theo de Witte, MD PhD

Blood (2016) 128 (22): 4327.

https://doi.org/10.1182/blood.V128.22.4327.4327

Published: 2016

Journal Articles

Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma

Blood (2016) 128 (22): 993.

https://doi.org/10.1182/blood.V128.22.993.993

Published: 2016

Journal Articles

Deregulated Expression of Long Non-Coding RNAs UCA1, NEAT1 and BDNF-As in Multiple Myeloma

Lenka Sedlarikova, MSc, Barbora Gromesova, MSc, Jana Filipova, MSc, Veronika Kubaczkova, MSc, Lenka Radova, PhD, Martina Almasi, PhD, Miroslav Penka, MD PhD, Zdenek Adam, MD PhD, Ludek Pour, MD PhD, Marta Krejci, MD PhD, Sabina Sevcikova, RNDr, PhD, Roman Hajek, prof, MD PhD

Blood (2016) 128 (22): 2073.

https://doi.org/10.1182/blood.V128.22.2073.2073

Published: 2016

Journal Articles

Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry

Louise De Swart, MD, Chloé Reiniers, Tim Bagguley, David Bowen, MD PhD, Jaroslav Cermak, MD PhD, Eva Hellström-Lindberg, MD PhD, Aurelia Tatic, MD, Argiris Symeonidis, MD PhD, Gerwin Huls, MD PhD, Panagiotis Panagiotidis, Hege Garelius, MD, Dominic Culligan, Marta Krejci, Corine van Marrewijk, Jackie Droste, PhD, Alexandra Smith, Dorine W. Swinkels, MD PhD, Theo de Witte, MD PhD

Blood (2015) 126 (23): 2865.

https://doi.org/10.1182/blood.V126.23.2865.2865

Published: 2015

Journal Articles

Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients

Lenka Kubiczkova-Besse, Lenka Sedlarikova, Fedor Kryukov, Lenka Radova, PhD, Jana Nekvindova, Pavel Nemec, Daniela Drandi, Simona Caltagirone, Paola Omedè, PhD, Marta Krejci, As Prof, MD PhD, Zdenek Adam, prof, MD PhD, Ludek Pour, Doc, MD PhD, Sabina Sevcikova, PhD, Antonio Palumbo, MD, Mario Boccadoro, Roman Hajek, Prof, MD PhD

Blood (2014) 124 (21): 2043.

https://doi.org/10.1182/blood.V124.21.2043.2043

Published: 2014

Journal Articles

Subcutaneous and Intravenous Bortezomib in Multiple Myeloma Patients Has Similar Response Rates and Toxicity Profile with No Difference in the Incidence of Peripheral Neuropathy: Report of the Czech Myeloma Group

Blood (2014) 124 (21): 2117.

https://doi.org/10.1182/blood.V124.21.2117.2117

Published: 2014

Journal Articles

Combination Of Lenalidomide, Dexamethasone and Cyclophosphamide as Treatment For The First Relapse Of Multiple Myeloma: Efficacy, Toxicity and Occurance Of Thyroid Abnormalities

Marta Krejci, MD, PhD, Zdenek Adam, Prof. MD, PhD, Ludek Pour, MD, PhD, Jana Pelcova, Jiri Mayer, MD, PhD

Blood (2013) 122 (21): 3233.

https://doi.org/10.1182/blood.V122.21.3233.3233

Published: 2013

Journal Articles

Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Prognostic Significance of Complete Response.

Marta Krejci, MD, PhD, Roman Hajek, Prof. MD, PhD, Zdenek Adam, Prof. MD, PhD, Ludek Pour, MD, PhD, Lenka Zahradova, MD, PhD, Jana Pelcova, Jiri Mayer, M.D., PhD., Prof.

Blood (2012) 120 (21): 3126.

https://doi.org/10.1182/blood.V120.21.3126.3126

Published: 2012

Journal Articles

High-Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma: Analysis from Registry of Monoclonal Gammopathy of Czech Myeloma Group

Roman Hajek, Prof. MD, PhD, Ivan Spicka, As. Prof. MD, PhD, Vladimir Maisnar, As. Prof. MD, PhD, Tomas Pika, MD, PhD, Evzen Gregora, MD, Lenka Zahradova, MD, PhD, Jan Straub, MD, Jakub Radocha, MD, PhD, Jiri Minarik, MD, PhD, Petr Pavlicek, MD, Marta Krejci, As. Prof. MD, PhD, Ludek Pour, MD, PhD, Zdenek Adam, Prof. MD, PhD, Vlastimil Scudla, Prof. MD, PhD

Blood (2012) 120 (21): 4528.

https://doi.org/10.1182/blood.V120.21.4528.4528

Published: 2012

Journal Articles

Similar Efficacy of Thalidomide-Based and Bortezomib-Based Regimens In the First Relapse of 209 Multiple Myeloma Patients Previously Untreated with Novel Drugs

Marta Krejci, Evzen Gregora, Ivan Spicka, Vlastimil Scudla, Jan Straub, Jiri Minarik, Zdenek Adam, Andrea Krivanova, Ludek Pour, Lenka Zahradova, Jiri Mayer, MD, PhD, Roman Hajek

Blood (2010) 116 (21): 5027.

https://doi.org/10.1182/blood.V116.21.5027.5027

Published: 2010

Journal Articles

Prognostic Significance of Morphological Evaluation of Tumor Cells in Multiple Myeloma.

Mohammed Al-sahmani, MD, Irena Trnavska, Monika Antosova, Libuse Antosova, Jarmila Kissova, MD, Hana Filkova, M.Sc., Jan Smetana, M.Sc., Zdenek Adam, MD, Prof., Ludek Pour, MD, Marta Krejci, MD, Lenka Zahradova, MD, Alena Bulikova, MD, Miroslav Penka, Prof., Petr Kuglik, Ass., Prof., Roman Hajek, MD, Prof.

Blood (2009) 114 (22): 4889.

https://doi.org/10.1182/blood.V114.22.4889.4889

Published: 2009

Journal Articles

Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia with Normal Karyotype: A Risk Factor Analysis in 247 Patients, Based On Molecular Markers and Stage at Transplantation.

Blood (2009) 114 (22): 1209.

https://doi.org/10.1182/blood.V114.22.1209.1209

Published: 2009

Journal Articles

Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Benefit from the Newer Drugs Used in the Relapsed Setting.

Blood (2008) 112 (11): 3331.

https://doi.org/10.1182/blood.V112.11.3331.3331

Published: 2008

Journal Articles

The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance

Roman Hajek, Lenka Zahradova, Evzen Gregora, Miroslava Schutzova, Vladimir Koza, Petr Pavlicek, Ludek Pour, Marta Krejci, Viera Sandecka, Andrea Krivanova, Mohammed Al Sahmani, Dana Kralova, Zdenek Adam

Blood (2008) 112 (11): 3699.

https://doi.org/10.1182/blood.V112.11.3699.3699

Published: 2008

Journal Articles

New Characteristics of Liver Gvhd: Kinetics, and the Serum Levels of Enzymes Linked to Cholestasis

Jiri Mayer, MD, Jan Kamelander, MD, Zdenek Pospisil, MSc, Michael Doubek, MD, PhD, Marta Krejci, MD, PhD

Blood (2008) 112 (11): 4359.

https://doi.org/10.1182/blood.V112.11.4359.4359

Published: 2008

NARROW

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic

Tumor Specific cfDNA Predicts Treatment Response of Multiple Myeloma Patients

Diagnostic Relevance of 18F-FDG PET/CT in Newly Diagnosed Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) : Single- Center Experience

Risk Factors Associated with Development of Extramedullary Disease in Multiple Myeloma

Bortezomib-Based Induction Treatment for Patients with Multiple Myeloma Ineligible for Autologous Stem Cell Transplantation: A Retrospective Multicenter Study in Czech Republic

Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry

Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma

Deregulated Expression of Long Non-Coding RNAs UCA1, NEAT1 and BDNF-As in Multiple Myeloma

Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry

Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients

Subcutaneous and Intravenous Bortezomib in Multiple Myeloma Patients Has Similar Response Rates and Toxicity Profile with No Difference in the Incidence of Peripheral Neuropathy: Report of the Czech Myeloma Group

Combination Of Lenalidomide, Dexamethasone and Cyclophosphamide as Treatment For The First Relapse Of Multiple Myeloma: Efficacy, Toxicity and Occurance Of Thyroid Abnormalities

Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Prognostic Significance of Complete Response.

High-Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma: Analysis from Registry of Monoclonal Gammopathy of Czech Myeloma Group

Similar Efficacy of Thalidomide-Based and Bortezomib-Based Regimens In the First Relapse of 209 Multiple Myeloma Patients Previously Untreated with Novel Drugs

Prognostic Significance of Morphological Evaluation of Tumor Cells in Multiple Myeloma.

Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia with Normal Karyotype: A Risk Factor Analysis in 247 Patients, Based On Molecular Markers and Stage at Transplantation.

Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Benefit from the Newer Drugs Used in the Relapsed Setting.

The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance

New Characteristics of Liver Gvhd: Kinetics, and the Serum Levels of Enzymes Linked to Cholestasis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only